Bill Haslam's plan to extend Medicaid to 280,000 low-income Tennesseans now is targeting 230,000 people already covered under the federal health insurance exchange. Brian Kelsey's bill would block Tennessee from creating its own state-run exchange if opponents to the Affordable Care Act, known as Obamacare, lose their latest legal challenge.
Meanwhile, Senate Majority Leader Bill Galvano, R- Bradenton, says he definitely wants to look at Senate. Galvano has also called for expanding Medicaid under the Affordable Care Act, commonly known as Obamacare. Rick Scott has said he supports the expansion of Medicaid as well, but both Boyd and Steube indicate that House leadership support for ap
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA New research indicates that hormonal intrauterine devices and contraceptive implants remain highly effective one year beyond their approved duration of use, according to a study at Washington University School of Medicine in St. Louis. The researchers are evaluating whether su
Feb. 28 Years before the most recent community health needs assessment, the Grand Haven- based North Ottawa Community Health System started working to bolster its primary care foundation. When the 2012 assessment indicated area residents need more access to medical care, it helped validate the health system's efforts, said NOCHS spokeswoman Jen V
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Investigators publish new report on Halogens. According to news reporting from Tucson, Arizona, by NewsRx journalists, research stated, "The diversity of elements among U.S. Food and Drug Administration approved pharmaceuticals is analyzed and reported, with a focus on atoms o
Baltimore s Asklepion Pharmaceuticals which counts the New Zealand breakfast cereal maker as an investor secured an acquisition agreement with New York- based Retrophin in January. Retrophin has acquired the worldwide rights to Asklepion s colic acid treatment for a deadly genetic liver defect, provided the drug receives US Food and Dru
Suhail Abdulla Al-Rukn, neurology consultant and stroke specialist at the Neurology Department of Rashid Hospital in Dubai, explains the importance of the "Stroke Initiative" program at the recent launching while other participants listen.- Courtesy photo.. In the Middle East and North Africa, stroke is increasingly becoming a major health issue, w
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell...
Eagle Pharmaceuticals confirmed that the U.S. Food and Drug Administration has granted seven years of market exclusivity in the U.S. to Ryanodex for Injectable Suspension for the treatment of malignant hyperthermia. According to a release from the company, Ryanodex was designated an orphan drug in August 2013 and was approved by the FDA in July 201
Infinity Pharmaceuticals reported its full-year 2014 financial results and ongoing progress with duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase- delta and PI3K-gamma. "In 2014, Infinity continued to advance duvelisib in registration- focused studies and entered a global collaboration with AbbVie to expand and accelerate the...
Actavis, Irish specialty pharmaceutical firm entered an abbreviated new drug application to the US Food and Drug Administration want approval to market Budesonide Extended-release Tablets, 9 mg. Earlier in February 2015, Santarus and Cosmo Technologies filed a lawsuit, under provisions of the Hatch-Waxman Act, against Actavis in the US District Cou
Research and Markets has added the "IVD Procedure Volumes and Pricing Analysis" report to its offerings. In a release, Research and Markets noted that report highlights include:. Clinical laboratory medicine plays an integral role in healthcare and disease management, as it estimated that approximately 80 percent of physician's diagnoses are a resu
Feb. 27 ENID, Okla. St. Mary's Regional Medical Center is focused on the future with one eye on its past. G.A. Boyle as a 12- bed facility called Enid Spring Sanatorium and Baths. Mary's chief executive officer, said an anniversary dinner is planned for this spring at Enid Event Center.
Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency has accepted the Marketing Authorization Application of Kyprolis for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. Achieving deep and durable responses for patients with...
VertiFlex reported that the U.S. Food and Drug Administration's Orthopedic and Rehabilitation Devices Advisory Panel has voted strongly in support of the PreMarket Approval application for the company's Superion Interspinous Spacer System. We will continue to work closely with the FDA to complete their review of our PMA while we finalize plans for.
We market three FDA- approved therapies, including Ampyra Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis, or MS, as demonstrated by an increase in walking speed. In October 2014, we acquired Civitas Therapeutics, Inc., a biopharmaceutical company which is developing CVT-301, a Phase 3 treatment c
DUBLIN and SAN FRANCISCO, Feb. 27, 2015/ PRNewswire/ Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA? by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. Actavis and Medic
Actavis on February 24 confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Budesonide Extended- release Tablets, 9 mg. Cosmo Technologies Limited and Santarus, Inc. filed suit against Actavis on February 17, in the U.S. District Court for the District of Delaware seek
WASHINGTON- Actavis plc, a global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA by the U.S. Food and Drug Administration or FDA for use by women to prevent pregnancy for up to three years. Actavis and Medicines360's groundbreaking partnership would allo
Several standard treatments cost more than $1,000 per month on many Coventry Health Care and Humana plans, while some of the same drugs cost as little as $35 on plans other insurers sell on the exchange, according to an AIDS Foundation of Chicago analysis. The AIDS Foundation warned Coventry, Humana and two other insurers in January letters that th
The Company has two divisions, Home Health Care and Healthcare Innovations. The Home Health Care division is comprised of two reportable segments, Visiting Nurse Services and Personal Care Services. Approximately 94% of the VN segment revenues are generated from the Medicare program while the balance is generated from Medicaid and private insurance
Switzerland- based color and specialty chemicals company Archroma has received FDA approval for the use of its new Cartaguard KST additive in the manufacture of paper and board for food packaging. The product has been approved by the US Federal Food and Drug Administration under 21 CFR 176.170 and can be used as a grease resistance treatment before
*Study Meets Primary Endpoint and Achieves Low Bleeding Rates with Once- Weekly Prophylactic Dosing in Children* Results Support EU Regulatory Submission and Future Paediatric Indication Applications Biogen Idec and Swedish Orphan Biovitrum AB today announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the...
Anna G. Eshoo and Leonard J. Lance for leading the charge to protect the FDA from the serious threat of potential future user fee cuts brought on by sequestration. It would not be possible for the United States ? with California front and center ? to become the global leader in life sciences innovation, without adequate funding of FDA, incl
Capricor Therapeutics, Inc., a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Thomas Copmann, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs and Drug Development. In this role, Dr. Copmann will lead the company's reg